Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002174 · ClinicalTrials.gov registry record · NA
Further Evaluation of Thalidomide's Ability to Potentiate the Immune Response to HIV-Infected Patients
A NA study, sponsored by Louisiana State University Health Sciences Center in New Orleans.
- Completed
- Registry status
- NA
- Development phase
- 20
- Enrollment target
NCT00002174 is a NA study that has completed, run by Louisiana State University Health Sciences Center in New Orleans. The registered enrollment target is 20 participants.
The verdict
NCT00002174, a NA study, has completed, sponsored by Louisiana State University Health Sciences Center in New Orleans.
- COMPLETED
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
Study Summary
To determine if Thalidomide modulates the production of HIV-suppressor factors (MIP-1 alpha, MIP-1 beta, Rantes) and TH1 type cytokines (IL-12 and INF-gamma) in HIV-infected patients and alters viral load.
Interventions
- DRUG Thalidomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002174
The ClinicalTrials.gov registry entry for NCT00002174 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Louisiana State University Health Sciences Center in New Orleans, which has 45 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Thalidomide is the first listed.
NCT00002174 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002174 about?
NCT00002174 is a clinical study titled "Further Evaluation of Thalidomide's Ability to Potentiate the Immune Response to HIV-Infected Patients". To determine if Thalidomide modulates the production of HIV-suppressor factors (MIP-1 alpha, MIP-1 beta, Rantes) and TH1 type cytokines (IL-12 and INF-gamma) in HIV-infected patients and alters viral load.
What is the current status of trial NCT00002174?
This trial is currently completed. It is a NA study. The enrollment target is 20 participants.
What interventions are being tested in trial NCT00002174?
The interventions under investigation include: Thalidomide (DRUG).
Who is sponsoring clinical trial NCT00002174?
This trial is sponsored by Louisiana State University Health Sciences Center in New Orleans, which has 45 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.